RCKT Stock — Rocket Pharmaceuticals, Inc.: Metrics

Market overview

2 metrics

Share price

$3.73

Market cap

$409.46M

Price action

19 metrics

Price change (1W)

-1.3%

Price change (30D)

+9.4%

Price change (3M)

+29.1%

Price change (6M)

-22.3%

Price change (YTD)

+6.3%

Price change (1Y)

+13.7%

Trailing year

Price change (5Y)

-89.8%

52-week high

$5.30

52-week low

$2.60

Change from 52-week high

-29.6%

Change from 52-week low

+43.5%

Annualized volatility

71.2%

Beta

1.9

RSI (14D)

56.4

Price vs SMA 50

+5.8%

Price vs SMA 200

+4.6%

Avg volume (3M)

2.16M

Relative volume

0.4

Average dollar volume

$7.27M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

109.77M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

1.1

reciprocal yield 90.1%

FCF yield

—

TTM · current market cap

Buyback yield

0.0%

P / FCF

—

P / operating cash flow

—

Earnings yield

-4.2%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

0.0%

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-03-27

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$191.64M

Net income (TTM)

−$17.25M

Trailing 12 months

Diluted EPS (TTM)

$-0.17

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-50.54

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

—

Revenue (TTM)

$0

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+3.1%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-4.7%

Return on assets

-4.1%

Debt / equity

—

Current ratio

9.2

EBITDA (TTM)

−$184.04M

Free cash flow (TTM)

—

Quick ratio

9.2

Interest coverage

-101.3

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$283.75M

Latest balance sheet

Cash & equivalents

$224.51M

Total assets

$423.10M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$170.27M

Capital expenditures (TTM)

—

R&D (TTM)

$124.37M

SG&A (TTM)

—

Stock compensation (TTM)

$31.78M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

186

13F filer change QoQ

-14

Institutional ownership

92.7%

Short interest

3 metrics

Short interest

13.1%

Latest settlement · 8.6 days to cover

Days to cover

8.6d

Short-squeeze score

68 / 100

Insider activity

2 metrics

Net insider buying (90D)

−$176,003

Insider-sentiment score

30 / 100

Risk flags

1 metrics

Going concern

—

RCKT · Rocket Pharmaceuticals, Inc.

RCKT metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search